Previous Article | Next Article ![]()
Molecular and Cellular Biology, November 2003, p. 7708-7718, Vol. 23, No. 21
0270-7306/03/$08.00+0 DOI: 10.1128/MCB.23.21.7708-7718.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada M5G 2C1,1 Institute for Molecular Biotechnology of the Austrian Academy of Sciences, A-1030 Vienna, Austria,2 Program in Developmental Biology, The Hospital for Sick Children, and Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario, Canada M5G 1X8,3 Regulation of Protein Function Laboratory, National Cancer InstituteFrederick, NIH, Frederick, Maryland 217024
Received 23 January 2003/ Returned for modification 10 April 2003/ Accepted 23 July 2003
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Studies of Sli-1 and D-Cbl have established the role of Cbl proteins in C. elegans vulval development and Drosophila photoreceptor development and oogenesis as negative regulators of signaling from epidermal growth factor receptor (EGFR) homologs (16, 27, 34, 51). Similarly, in mammals, c-Cbl and Cbl-b are phosphorylated and recruited to the EGFR upon epidermal growth factor (EGF) stimulation and also interact with multiple intracellular signaling intermediates. Numerous overexpression studies have demonstrated that c-Cbl and Cbl-b are negative regulators of tyrosine kinase signaling (reviewed in references 44 and 47). Gene targeting studies of c-Cbl and Cbl-b have demonstrated that these proteins are important negative regulators of immunoreceptor signaling in thymocytes and mature T cells, respectively (1, 4, 31, 32). However, the roles of Cbl proteins appear to be complex, since c-Cbl or Cbl-b may also play positive regulatory roles in bone resorption, glucose transport, integrin-mediated adhesion, and T-cell receptor signaling (2, 8, 43, 52, 53).
An important breakthrough in our understanding of the mechanism by which Cbl proteins mediate their negative regulatory function came with the discovery that Cbl proteins act as ubiquitin ligases. Modification of receptor tyrosine kinases with ubiquitin terminates signaling by targeting these receptors for degradation (35, 50). Ubiquitination is a sequential process involving a ubiquitin-activating enzyme, or E1, a ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase (E3). Cbl proteins have been shown to act as ubiquitin protein ligases by mediating the transfer of ubiquitin onto receptor tyrosine kinases, so enhancing their degradation (15, 23, 30). The conserved Cbl amino-terminal TKB, linker, and RING finger domains are sufficient for ubiquitin ligase activity (24).
Cbl-3 is the most recent mammalian cbl family member to be identified in humans (17, 20) and mice (9). Like other cbl's, Cbl-3 contains conserved amino-terminal TKB, linker, and RING finger regions. However, Cbl-3 possesses a much shorter proline-rich region than c-Cbl and Cbl-b and lacks their carboxy-terminal leucine zipper motif (17, 20). Nonetheless, the proline-rich region of Cbl-3 has been demonstrated to bind to various SH3 domain-containing proteins, including those of src family kinases such as Fyn (17, 20). An alternatively spliced form of human Cbl-3 termed Cbl-3S, which lacks part of the TKB domain, has also been reported in humans (17). Overexpression studies have shown that, like other cbl's, Cbl-3 is recruited to the EGFR upon EGF stimulation (17, 20). Cbl-3 functions as a negative regulator since overexpression of this protein attenuates EGF-stimulated mitogen-activated protein kinase activation and Elk-1 transactivation in 293T cells (17). Moreover, Cbl-3 appears to have ubiquitin ligase activity, since its overexpression results in enhanced endocytosis, ubiquitination, and degradation of the EGFR upon EGF stimulation (23). Cbl-3 has also been found to interact with the homologous-to-E6-associated-protein-C-terminus domain-containing E3 ligase Itch/AIP4 (5).
Cbl-3 has an expression pattern distinct from those of the other mammalian family members. While c-Cbl and Cbl-b are highly expressed in hematopoietic tissues and the testes (18, 22), Cbl-3 is not expressed in these organs and is instead expressed in the gastrointestinal tract, liver, kidney, pancreas, and prostate (17, 20). However, the physiological roles of Cbl-3 remain unknown. Here we report the detailed expression pattern of murine Cbl-3 and utilize gene-targeted deletion of Cbl-3 to characterize the requirements for this protein in vivo.
| MATERIALS AND METHODS |
|---|
|
|
|---|
The targeting vector was linearized with NotI and electroporated into E14K embryonic stem (ES) cells. The ES cells were selected in medium containing 300 µg of G418/ml and 2 µM ganciclovir. Four hundred G418- and ganciclovir-resistant ES cell colonies were picked and screened for homologous recombination by using PCR with two sets of primers, one of which was specific for the neomycin resistance cassette (5'-CCA GCT CAT TCC TCC CAC TC-3' and 5'-GGA AGG ATT GGA GCT ACG GGG GTG-3') and the other of which comprised flanking primers specific for a region of intron 1 (5'-GCC AGA CCC AAA TCA CCA GTT TAG-3' and 5'-AGT TTA GAC CTT GCT CTG GGT TCC-3'). Positive colonies were further analyzed by digestion of their genomic DNA with SpeI, followed by Southern blotting with a 250-bp external random hexamer 32P-labeled DNA probe located 5' of the long arm to confirm that homologous recombination had occurred. To confirm that the ES cells had undergone a single recombination event, genomic DNA was digested with NcoI and hybridized with a Neor gene-specific probe.
Six correctly targeted ES cell clones were identified, and four were microinjected into 3.5-day-old C57BL/6J blastocysts. Backcrossing of chimeric males with C57BL/6 females resulted in establishment of three independent Cbl-3-/- mouse strains as verified by Southern blotting. For PCR genotyping, the mutant locus was detected as described above and the wild-type locus was detected with a primer specific for Cbl-3 exon 1 (5'-CAG CTA CTT GGA GAG GTG GCA AAG-3') and the flanking primers described above. No differences in phenotypes were detected among Cbl-3-deficient mice derived from the three different ES cell clones. Mice were maintained at the animal facilities of the Ontario Cancer Institute under specific-pathogen-free conditions according to institutional guidelines.
Northern blot analysis.
To confirm loss of Cbl-3 expression in gene-targeted mice, total RNA was isolated from various mouse tissues by using TRIZOL reagent (Gibco BRL) according to the manufacturer's instructions. For Northern analysis, total RNA (30 µg/lane) was electrophoresed through 1% agarose-formaldehyde gels. Northern blots were hybridized with Cbl-3- or ß-actin (Clontech)-specific [
-32P]dCTP-labeled cDNA probes. Two Cbl-3-specific probes were used that recognized either exons 2 to 7 or exons 4 to 8 (both of which are 3' of the targeted region), with comparable results.
Detection of ß-galactosidase expression. Immediately after sacrifice, mice were perfused with ice-cold Ca2+- and Mg2+-free phosphate-buffered saline (PBS) followed by 1% glutaraldehyde. Organs were removed and further fixed for 1 h at room temperature in fixative solution containing 0.2% glutaraldehyde, 2% formaldehyde, 2 mM MgCl2, and 5 mM EGTA in 0.1 M phosphate buffer. After being washed in wash buffer containing 2 mM MgCl2, 0.02% NP-40, and 0.01% sodium deoxycholate in 0.1 M phosphate buffer, organs were incubated for 1 h in 15% sucrose in PBS at 4°C and then overnight in 30% sucrose in PBS at 4°C. Organs were then embedded in Tissue Tek OCT compound (Sakura) and frozen on dry ice. Cryosections (10 and 40 µm) were fixed again in fixative solution minus formaldehyde for 10 min, washed three times in wash buffer, and stained overnight at 37°C in wash buffer containing 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, and 1 mg of 4-chromo-5-bromo-3-indolyl-ß-D-galactosidase (X-Gal; Gibco BRL)/ml. X-Gal is hydrolyzed by ß-galactosidase to form a blue precipitate. Slides were counterstained with nuclear fast red, dehydrated, and mounted in Entellan mounting medium.
Analysis of Cbl-3 expression by in situ hybridization. Mice were sacrificed by cervical dislocation and immediately perfused with ice-cold Ca2+- and Mg2+-free PBS for 3 min followed by 4% paraformaldehyde (PFA) in Ca2+- and Mg2+-free PBS for 10 min. Organs were removed and fixed further in 4% PFA overnight at 4°C, dehydrated, and embedded in paraffin blocks. In situ hybridization of paraffin sections was performed as described previously (14).
Histology and immunohistochemistry. For hematoxylin and eosin (H&E) staining, tissues were fixed with 4% PFA as described above and 3-µm-thick paraffin sections were stained with H&E. For immunohistochemistry, heat-induced epitope retrieval was carried out in 10 mM citrate buffer, pH 6.0. Sections were incubated with monoclonal rat anti-mouse Ki67 (DAKO) at a 1/150 dilution for 1 h at room temperature, followed by biotinylated rabbit anti-rat immunoglobulin G, streptavidin-horseradish peroxidase, and diaminobenzidine tetrahydrochloride reagent.
Isolation and stimulation of primary keratinocytes. Keratinocytes were isolated from 1- to 5-day-old littermate mice as previously described (13), with the following modifications: (i) skins were floated overnight in Dispase II (Roche) to separate dermises from epidermises, and (ii) keratinocytes were cultured on collagen I- or IV-coated plates (BD Biocoat cellware) in KGM-2 medium (Clonetics). Once keratinocytes were almost confluent, cells were starved overnight in KGM (Clonetics) containing only antibiotics and 0.1% fatty acid-free bovine serum albumin (Sigma). Keratinocytes were stimulated in starvation medium containing 10 ng of EGF (Peprotech)/ml and lysed in radioimmunoprecipitation assay buffer. Western blots were probed with anti-phospho-Erk1,2 (Cell Signaling), stripped, and reprobed with antibody that detects total Erk1 and Erk2 proteins (Cell Signaling). To detect protein expression levels, lysates of unstimulated keratinocytes were probed with rabbit anti-c-Cbl (Santa Cruz), mouse anti-Cbl-b (Santa Cruz), or rabbit anti-keratin 1 (Cedarlane).
| RESULTS |
|---|
|
|
|---|
|
Cbl-3 is not required for viability. To determine whether Cbl-3 is required during development, offspring from Cbl-3+/- intercrosses were genotyped by PCR at 3 weeks of age. Normal Mendelian ratios of Cbl-3+/+, Cbl-3+/-, and Cbl-3-/- offspring were observed, indicating that Cbl-3 is not required for embryogenesis or postnatal survival (Table 1). Breeding of male and female Cbl-3-/- mice resulted in healthy offspring, indicating that Cbl-3 is not necessary for fertility. Cbl-3-/- mice did not exhibit any increases in mortality or disease compared to Cbl-3+/- or Cbl-3+/+ control littermates up to 18 months of age. Thus, Cbl-3 is dispensable for development and is not required for viability or fertility.
|
Since organs where Cbl-3 expression is detected contain multiple tissue and cell typesfor example, smooth muscle, connective tissue, and epithelial cells in the intestineNorthern blotting could not reveal the cell type specificity of Cbl-3 expression. Thus, we made use of the lacZ gene, which was inserted in place of Cbl-3 exon 1 by our gene targeting strategy, to facilitate the analysis of Cbl-3 expression. X-Gal staining for ß-galactosidase activity was performed on various tissues from Cbl-3+/+, Cbl-3+/-, and Cbl-3-/- mice. In agreement with previous Northern blotting results (17, 20), we observed X-Gal staining in the tracheas, small intestines, kidney tubules, and livers of Cbl-3+/- and Cbl-3-/- mice (Fig. 2 and data not shown). Interestingly, in all these tissues, X-Gal staining was found only in epithelial cells. In the small intestines, X-Gal staining was detected in epithelial cells of the villi but not in those of the crypts. The stratified squamous epithelia of the rectums and biliary epithelial cells of the livers were also positive for ß-galactosidase activity. However, X-Gal staining was not detected in the pancreases or prostates, which do show Cbl-3 expression in humans as detected by Northern blot analysis (17, 20). X-Gal staining also revealed novel Cbl-3 expression in the epidermises, bronchi and bronchioles of the lungs, transitional epithelia of the bladders, mammary epithelia, uterine endometria, vaginas, epithelial linings of the epididymides, esophagi, and stomachs (Fig. 2 and data not shown). Consistent with results of Northern analysis, organs such as the lymph nodes, thymuses, hearts, and skeletal muscles showed no increase in X-Gal staining in Cbl-3+/- and Cbl-3-/- mice. Additionally, no X-Gal staining was seen in the bones or the eyes.
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Through a combined approach of X-Gal staining and in situ hybridization, we demonstrated that Cbl-3 expression is restricted to epithelial cells. Cbl-3 expression was not observed in nonepithelial tissues. Within the epithelial lineage, Cbl-3 expression levels varied significantly between different organs and different regions within an organ. For example, in the lungs, Cbl-3 expression was seen in the bronchi and bronchioles but not in the surrounding alveoli. Since other cbl family members have been shown to negatively regulate antigen receptor-stimulated proliferation in lymphocytes and EGFR signaling in cell lines, we hypothesized that Cbl-3 deficiency would lead to defects in development and/or increased proliferation due to enhanced signaling from growth factor receptors. However, surprisingly, no developmental abnormalities were seen in Cbl-3-/- mice. Proliferation in the small intestine is restricted to the crypts of Lieberkühn, whereas the villi are composed of differentiated enterocytes, goblet cells, and enteroendocrine cells (3, 33, 42). Since Cbl-3 expression is enriched in nonproliferative, differentiated cells of the small intestine, we hypothesized that Cbl-3 may negatively regulate the proliferative potential of these cells. However, basal levels of proliferation in the gastrointestinal tract and epidermis were unaffected by Cbl-3 deficiency. Moreover, the kinetics of EGF-induced mitogen-activated protein kinase activation in primary keratinocytes were unchanged by Cbl-3 deficiency.
The reasons for the lack of requirement for Cbl-3 for epithelial development and function in vivo are unclear, but this finding may be due to compensation between Cbl family members. Whereas C. elegans possesses only one Cbl gene, humans and mice have three different Cbl family members. The presence of multiple Cbl proteins in mammals, all with conserved TKB and RING finger domains, suggests that there may be functional compensation between Cbl family members. Indeed, while mice deficient in c-Cbl or Cbl-b display mild defects that are for the most part limited to the immune system, mice deficient in both c-Cbl and Cbl-b have an early embryonic lethal phenotype (25, 36). Although highest expression levels of c-Cbl and Cbl-b are found in hematopoietic tissues and the testes, these two proteins are also expressed in epithelial cells, including keratinocytes (10, 18, 26). To address the issue of functional redundancy, Cbl-3-deficient mice will be intercrossed with c-Cbl- and Cbl-b-deficient mice to generate Cbl-3/c-Cbl and Cbl-3/Cbl-b double-deficient animals.
Epithelial tissues undergo continuous regeneration, and most tumors arise from epithelial tissues (Ontario Cancer Registry, 2000). Alterations in EGFR signaling can lead to epithelial tumor formation. For example, human squamous cell carcinomas have a high frequency of EGFR gene amplifications, rearrangements, and overexpression (6, 37). Moreover, transgenic expression of transforming growth factor
or ErbB2 in the epidermis induces the development of papillomas and/or squamous cell carcinomas (7, 19, 49) and EGFR signaling has been found to be essential for Sos-dependent skin tumor formation (40). Since Cbl-3 has been shown to negatively regulate EGFR signaling in cell lines, the crossing of Cbl-3-, Cbl-3/c-Cbl-, and Cbl-3/Cbl-b-deficient mice with transgenic mice that are susceptible to epithelial tumors may help to reveal roles for this protein in tumor formation in vivo.
| ACKNOWLEDGMENTS |
|---|
E.K.G. is supported by a scholarship from the Natural Sciences and Engineering Research Council (NSERC) of Canada. J.M.P. is supported by grants from the Canadian Institute for Health Research (CIHR), the National Cancer Institute of Canada (NCIC), and the Institute for Molecular Biotechnology of the Austrian Academy of Sciences (IMBA). J.M.P. holds a Canada research chair in cell biology.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Baumann, C. A., V. Ribon, M. Kanzaki, D. C. Thurmond, S. Mora, S. Shigematsu, P. E. Bickel, J. E. Pessin, and A. R. Saltiel. 2000. CAP defines a second signalling pathway required for insulin-stimulated glucose transport. Nature 407:202-207.[CrossRef][Medline]
3. Bergman, R. A., A. K. Afifi, and P. M. Heidger. 1996. Histology. W. B. Saunders Company, Orlando, Fla.
4. Chiang, Y. J., H. K. Kole, K. Brown, M. Naramura, S. Fukuhara, R. J. Hu, I. K. Jang, J. S. Gutkind, E. Shevach, and H. Gu. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403:216-220.[CrossRef][Medline]
5. Courbard, J. R., F. Fiore, J. Adelaide, J. P. Borg, D. Birnbaum, and V. Ollendorff. 2002. Interaction between two ubiquitin-protein isopeptide ligases of different classes, CBLC and AIP4/ITCH. J. Biol. Chem. 277:45267-45275.
6. Derynck, R. 1992. The physiology of transforming growth factor-alpha. Adv. Cancer Res. 58:27-52.[Medline]
7. Dominey, A. M., X. J. Wang, L. E. King, Jr., L. B. Nanney, T. A. Gagne, K. Sellheyer, D. S. Bundman, M. A. Longley, J. A. Rothnagel, and D. A. Greenhalgh. 1993. Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas. Cell Growth Differ. 4:1071-1082.[Abstract]
8. Feshchenko, E. A., S. K. Shore, and A. Y. Tsygankov. 1999. Tyrosine phosphorylation of C-Cbl facilitates adhesion and spreading while suppressing anchorage-independent growth of V-Abl-transformed NIH3T3 fibroblasts. Oncogene 18:3703-3715.[CrossRef][Medline]
9. Fiore, F., V. Ollendorff, and D. Birnbaum. 2001. Characterization of the mouse Cblc/Cbl3 gene. Biochem. Biophys. Res. Commun. 280:182-187.[CrossRef][Medline]
10. Fukazawa, T., S. Miyake, V. Band, and H. Band. 1996. Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins. J. Biol. Chem. 271:14554-14559.
11. Giraud, A. S. 2000. X. Trefoil peptide and EGF receptor/ligand transgenic mice. Am. J. Physiol. Gastrointest. Liver Physiol. 278:G501-G506.
12. Hashimoto, K. 2000. Regulation of keratinocyte function by growth factors. J. Dermatol. Sci. 24(Suppl. 1):S46-S50.
13. Hennings, H. 1994. Primary culture of keratinocytes from newborn mouse epidermis in medium with lowered levels of Ca2+, p. 21-23. In I. Leigh and F. Watt (ed.), Keratinocyte methods. Cambridge University Press, Cambridge, United Kingdom.
14. Hui, C. C., and A. L. Joyner. 1993. A mouse model of greig cephalopolysyndactyly syndrome: the extra-toesJ mutation contains an intragenic deletion of the Gli3 gene. Nat. Genet. 3:241-246.[CrossRef][Medline]
15. Joazeiro, C. A., S. S. Wing, H. Huang, J. D. Leverson, T. Hunter, and Y. C. Liu. 1999. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 286:309-312.
16. Jongeward, G. D., T. R. Clandinin, and P. W. Sternberg. 1995. Sli-1, a negative regulator of let-23-mediated signaling in C. elegans. Genetics 139:1553-1566.[Abstract]
17. Keane, M. M., S. A. Ettenberg, M. M. Nau, P. Banerjee, M. Cuello, J. Penninger, and S. Lipkowitz. 1999. Cbl-3: a new mammalian cbl family protein. Oncogene 18:3365-3375.[CrossRef][Medline]
18. Keane, M. M., O. M. Rivero-Lezcano, J. A. Mitchell, K. C. Robbins, and S. Lipkowitz. 1995. Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10:2367-2377.[Medline]
19. Kiguchi, K., D. Bol, S. Carbajal, L. Beltran, S. Moats, K. Chan, J. Jorcano, and J. DiGiovanni. 2000. Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. Oncogene 19:4243-4254.[CrossRef][Medline]
20. Kim, M., T. Tezuka, Y. Suziki, S. Sugano, M. Hirai, and T. Yamamoto. 1999. Molecular cloning and characterization of a novel cbl-family gene, cbl-c. Gene 239:145-154.[CrossRef][Medline]
21. Langdon, W. Y., J. W. Hartley, S. P. Klinken, S. K. Ruscetti, and H. C. Morse III. 1989. v-cbl, an oncogene from a dual-recombinant murine retrovirus that induces early B-lineage lymphomas. Proc. Natl. Acad. Sci. USA 86:1168-1172.
22. Langdon, W. Y., C. D. Hyland, R. J. Grumont, and H. C. Morse III. 1989. The c-cbl proto-oncogene is preferentially expressed in thymus and testis tissue and encodes a nuclear protein. J. Virol. 63:5420-5424.
23. Levkowitz, G., H. Waterman, S. A. Ettenberg, M. Katz, A. Y. Tsygankov, I. Alroy, S. Lavi, K. Iwai, Y. Reiss, A. Ciechanover, S. Lipkowitz, and Y. Yarden. 1999. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4:1029-1040.[CrossRef][Medline]
24. Lill, N. L., P. Douillard, R. A. Awwad, S. Ota, M. L. Lupher, Jr., S. Miyake, N. Meissner-Lula, V. W. Hsu, and H. Band. 2000. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J. Biol. Chem. 275:367-377.
25. Liu, Y. C., and H. Gu. 2002. Cbl and Cbl-b in T-cell regulation. Trends Immunol. 23:140-143.[CrossRef][Medline]
26. Meisner, H., and M. P. Czech. 1995. Coupling of the proto-oncogene product c-Cbl to the epidermal growth factor receptor. J. Biol. Chem. 270:25332-25335.
27. Meisner, H., A. Daga, J. Buxton, B. Fernandez, A. Chawla, U. Banerjee, and M. P. Czech. 1997. Interactions of Drosophila Cbl with epidermal growth factor receptors and role of Cbl in R7 photoreceptor cell development. Mol. Cell. Biol. 17:2217-2225.[Abstract]
28. Meng, W., S. Sawasdikosol, S. J. Burakoff, and M. J. Eck. 1999. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature 398:84-90.[CrossRef][Medline]
29. Miettinen, P. J., J. E. Berger, J. Meneses, Y. Phung, R. A. Pedersen, Z. Werb, and R. Derynck. 1995. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376:337-341.[CrossRef][Medline]
30. Miyake, S., M. L. Lupher, Jr., B. Druker, and H. Band. 1998. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. Proc. Natl. Acad. Sci. USA 95:7927-7932.
31. Murphy, M. A., R. G. Schnall, D. J. Venter, L. Barnett, I. Bertoncello, C. B. Thien, W. Y. Langdon, and D. D. Bowtell. 1998. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol. Cell. Biol. 18:4872-4882.
32. Naramura, M., H. K. Kole, R. J. Hu, and H. Gu. 1998. Altered thymic positive selection and intracellular signals in Cbl-deficient mice. Proc. Natl. Acad. Sci. USA 95:15547-15552.
33. Pacha, J. 2000. Development of intestinal transport function in mammals. Physiol. Rev. 80:1633-1667.
34. Pai, L. M., G. Barcelo, and T. Schupbach. 2000. D-cbl, a negative regulator of the Egfr pathway, is required for dorsoventral patterning in Drosophila oogenesis. Cell 103:51-61.[CrossRef][Medline]
35. Pickart, C. M. 2001. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:503-533.[CrossRef][Medline]
36. Rao, N., I. Dodge, and H. Band. 2002. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J. Leukoc. Biol. 71:753-763.
37. Reichmann, E. 1994. Oncogenes and epithelial cell transformation. Semin. Cancer Biol. 5:157-165.[Medline]
38. Schlessinger, J. 2000. Cell signaling by receptor tyrosine kinases. Cell 103:211-225.[CrossRef][Medline]
39. Scholzen, T., and J. Gerdes. 2000. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182:311-322.[CrossRef][Medline]
40. Sibilia, M., A. Fleischmann, A. Behrens, L. Stingl, J. Carroll, F. M. Watt, J. Schlessinger, and E. F. Wagner. 2000. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 102:211-220.[CrossRef][Medline]
41. Sibilia, M., and E. F. Wagner. 1995. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science 269:234-238.
42. Stappenbeck, T. S., M. H. Wong, J. R. Saam, I. U. Mysorekar, and J. I. Gordon. 1998. Notes from some crypt watchers: regulation of renewal in the mouse intestinal epithelium. Curr. Opin. Cell Biol. 10:702-709.[CrossRef][Medline]
43. Tanaka, S., M. Amling, L. Neff, A. Peyman, E. Uhlmann, J. B. Levy, and R. Baron. 1996. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 383:528-531.[CrossRef][Medline]
44. Thien, C. B., and W. Y. Langdon. 2001. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell. Biol. 2:294-307.[CrossRef][Medline]
45. Threadgill, D. W., A. A. Dlugosz, L. A. Hansen, T. Tennenbaum, U. Lichti, D. Yee, C. LaMantia, T. Mourton, K. Herrup, R. C. Harris, J. A. Barnard, S. H. Yuspa, R. J. Coffey, and T. Magnuson. 1995. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269:230-234.
46. Tomic-Canic, M., M. Komine, I. M. Freedberg, and M. Blumenberg. 1998. Epidermal signal transduction and transcription factor activation in activated keratinocytes. J. Dermatol. Sci. 17:167-181.[CrossRef][Medline]
47. Tsygankov, A. Y., A. M. Teckchandani, E. A. Feshchenko, and G. Swaminathan. 2001. Beyond the RING: CBL proteins as multivalent adapters. Oncogene 20:6382-6402.[CrossRef][Medline]
48. van der Geer, P., T. Hunter, and R. A. Lindberg. 1994. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 10:251-337.[CrossRef][Medline]
49. Vassar, R., and E. Fuchs. 1991. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev. 5:714-727.
50. Weissman, A. M. 2001. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell. Biol. 2:169-178.[CrossRef][Medline]
51. Yoon, C. H., J. Lee, G. D. Jongeward, and P. W. Sternberg. 1995. Similarity of sli-1, a regulator of vulval development in C. elegans, to the mammalian proto-oncogene c-cbl. Science 269:1102-1105.
52. Zell, T., C. S. Warden, A. S. Chan, M. E. Cook, C. L. Dell, S. W. Hunt III, and Y. Shimizu. 1998. Regulation of beta 1-integrin-mediated cell adhesion by the Cbl adaptor protein. Curr. Biol. 8:814-822.[CrossRef][Medline]
53. Zhang, Z., C. Elly, L. Qiu, A. Altman, and Y. C. Liu. 1999. A direct interaction between the adaptor protein Cbl-b and the kinase zap-70 induces a positive signal in T cells. Curr. Biol. 9:203-206.[CrossRef][Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|